Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing by Small, B.G. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Efficient discovery of anti-inflammatory small-molecule
combinations using evolutionary computing
Citation for published version:
Small, BG, McColl, BW, Allmendinger, R, Pahle, J, Lopez-Castejon, G, Rothwell, NJ, Knowles, J, Mendes,
P, Brough, D & Kell, DB 2011, 'Efficient discovery of anti-inflammatory small-molecule combinations using
evolutionary computing' Nature Chemical Biology, vol. 7, no. 12, pp. 902-908. DOI: 10.1038/nchembio.689
Digital Object Identifier (DOI):
10.1038/nchembio.689
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Nature Chemical Biology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Efficient discovery of anti-inflammatory small molecule
combinations using evolutionary computing
Ben G Small1,8,$, Barry W McColl6,$, Richard Allmendinger4, Jürgen Pahle4, Gloria López-
Castejón3, Nancy J Rothwell3, Joshua Knowles4, Pedro Mendes2,4,5, David Brough3, and
Douglas B Kell2,7,*
1Doctoral Training Centre, Integrative Systems Biology Molecules to Life, University of
Manchester, 131 Princess Street, Manchester, M1 7DN, United Kingdom.
2Manchester Centre for Integrative Systems Biology, Manchester Interdisciplinary Biocentre,
University of Manchester, 131 Princess Street, Manchester, M1 7DN, United Kingdom.
3NeuroSystems, Faculty of Life Sciences, AV Hill Building, University of Manchester, Oxford
Road, Manchester, M13 9PT, United Kingdom.
4School of Computer Science, University of Manchester, Oxford Road, Manchester, M13 9PL,
United Kingdom.
5Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Washington
Street, MC0477, Blacksburg, Virginia, United States, 24061-0477.
6The Roslin Institute, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, United
Kingdom.
7School of Chemistry, University of Manchester, 131 Princess St, Manchester M1 7DN, United
Kingdom.
8School of Chemical Engineering and Analytical Science, University of Manchester, 131 Princess
St, Manchester M1 7DN, United Kingdom.
Abstract
The control of biochemical fluxes is distributed and to perturb complex intracellular networks
effectively it is often necessary to modulate several steps simultaneously. However, the number of
possible permutations leads to a combinatorial explosion in the number of experiments that would
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have to be performed in a complete analysis. We used a multi-objective evolutionary algorithm
(EA) to optimize reagent combinations from a dynamic chemical library of 33 compounds with
established or predicted targets in the regulatory network controlling IL-1β expression. The EA
converged on excellent solutions within 11 generations during which we studied just 550
combinations out of the potential search space of ~ 9 billion. The top five reagents with the
greatest contribution to combinatorial effects throughout the EA were then optimized pairwise. A
p38 MAPK inhibitor with either an inhibitor of IκB kinase or a chelator of poorly liganded iron
yielded synergistic inhibition of macrophage IL-1β expression. Evolutionary searches provide a
powerful and general approach to the discovery of novel combinations of pharmacological agents
with potentially greater therapeutic indices than those of single drugs.
Acute or chronic (non-resolving) inflammation is a well established mediator of major
diseases including vascular disease (e.g. atherosclerosis, stroke), chronic obstructive
pulmonary disease (COPD), cancer, diabetes, obesity, rheumatoid arthritis, psoriasis and
inflammatory bowel disease 1,2 . Each of these conditions exhibits an elevated expression of
the potent and pleiotropic, pro-inflammatory cytokine interleukin-1β (IL-1β) 2,3.
Pharmacological therapies targeted against IL-1β are largely focused on biologics that are
only likely to act extracellularly 4 (e.g. Anakinra; an IL-1 receptor antagonist), which have
shortcomings such as poor CNS penetration. Small molecule modulation of IL-1β may offer
benefits in certain conditions such as in cerebrovascular injury where IL-1β mediates
significant cerebral damage during acute ischaemia and excitotoxic insult 5.
The lipopolysaccharide- (LPS-) induced Toll-like receptor 4 (TLR4) stimulation of
macrophages is a widely used experimental model that mimics key aspects of inflammation
including IL-1β expression 6. Signal transduction induced by TLR4 stimulation proceeds
through the activation of a complex array of multi-protein signalling networks (e.g. MyD88,
TRAF6, p38 MAPK, NF-κB), ultimately resulting in the expression of the IL-1B gene.
Possibly based on the ‘one gene, one drug, one disease paradigm’ 7 a plethora of reagents
has been developed to modulate individual proteins within these signalling networks.
However, it is well known that multiple steps must be modulated simultaneously to have
significant effects on biochemical fluxes 8. Thus, a single-target approach is unlikely to be
optimal in inhibiting the expression of a pro-inflammatory cytokine such as IL-1β, where
there is both inherent degeneracy and considerable complexity within the signal transduction
network 9. More generally, there is an increasing recognition of the need to target multiple
steps within signalling networks for their effective pharmacological modulation 7.
Combinatorial chemical genetics 10 uses combinations of small molecules that allow
dissection of cellular phenomena via their selective modulation of individual biological
targets. Despite progress made in high-throughput screening technologies 11, the analysis of
even modestly sized chemical libraries is prohibitive due to the combinatorial explosion that
occurs in pharmacological space 12 (233 or ~ 9 billion combinations for all possible
combinations of the chemical library explored here). Thus we sought heuristic solutions (i.e.
reagent combinations) that are good but not provably globally optimal.
The terms ‘evolutionary computing’ and ‘evolutionary algorithms’ describe a set of
approaches based loosely on Darwinian evolution by the natural selection of individuals and
populations. In this case the population consists of individuals that each encode a candidate
solution to the problem at hand. The ‘fitness’ of each solution is reflected in the objective
function(s) designed by the experimenter, but normally includes the concept that fitter
individuals provide more accurate solutions. There may be multiple fitness functions. For
instance a simpler solution may be deemed to be a fitter solution, and algorithms with
multiple objectives (multiple fitnesses), as in this work, are known as multi-objective
evolutionary algorithms. Multi-objective evolutionary algorithms (EA) allow for the
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specification of multiple and distinct optimization objectives and their simultaneous
handling 13-15. Based on the fitness(es), a selection step determines which individuals will
be allowed to remain under consideration for the next generation. Some of these individuals
are retained by simply being copied unchanged into the subsequent generation(s), but new
diversity, based on the parents selected, is then produced from them by processes analogous
to mutation and recombination. The fitnesses of these new individuals are then evaluated as
above, and the algorithm continues cycling through the steps of selection, breeding and
fitness evaluation until an acceptable solution is found. Decades of research within the field
of evolutionary computing (e.g. 16,17) have revealed that optimization of multivariate
problems can be highly effective using small numbers of experimental tests. Although the
present study used an EA and an adaptive dose matrix search strategy, we recognize that
other kinds of combinatorial optimization approaches might also prove effective.
Using a ‘reverse’ combination chemical genetic approach 10 our aim was to optimize
combinations of reagents that minimize LPS-induced macrophage IL-1β expression, and
simultaneously minimize the number of component reagents in the combination and their
propensity to induce macrophage cell death. Subsequently we sought to optimize reagents to
inhibit IL-1β expression at concentrations lower than the component reagents used in
isolation. This was achieved by application of an EA-directed, semi-automated robotic assay
of IL-1β expression to a dynamic chemical library of a total of 33 reagents (see Methods,
and also 18-20). The specific algorithm used here was the Indicator Based Evolutionary
Algorithm (IBEA) 21, as in preliminary simulations 22 this proved superior to a variety of
other multi-objective optimization algorithms. This was followed by a dose matrix search of
top-ranked reagents resulting from the EA-directed search. We demonstrate that the EA
converges efficiently on good solutions, and that dual p38 MAPK inhibition and either IκB
kinase inhibition or iron chelation yields synergistic and biologically-relevant inhibition of
macrophage IL-1β expression.
Results
Rapid convergence of Multi-objective IBEA to near-optimal solutions
Concentration-effect curves for a selection of reagents with known or predicted targets in the
IL-1β expression network were determined in order to identify the most appropriate
concentration for use in the EA (Supplementary Results, Supplementary Fig. 2). On the
basis of these data we selected a sub-optimal dose (3μM) which would provide scope for
observing combinatorial synergy.
The Indicator Based Evolutionary Algorithm (IBEA) 21 directed a semi-automated robotic
assay utilizing chemical combinations to inhibit IL-1β expression was initialized (Fig. 1,
Loop 1). As described in Methods (Implementation of the Indicator Based Evolutionary
Algorithm (IBEA)), the IBEA generates subsets of combinations from the library and then
assesses the performance of these subsets with respect to inhibition of IL-1β expression,
decreases in LDH release (a marker for cell death) and the number of member reagents
within the combination. In the present case, we confined the number of experiments in each
of the first and subsequent generations to 50 and those for generation 1 were selected
randomly by the EA from the first-generation library of chemicals. Superior combinations
are retained and recombined with other library components in successive subsets and
assessed iteratively until satisfactory combinations are found. Assay of successive
generations of chemical combinations from a dynamic chemical library (a total of 33
reagents, each at a concentration of 3 μM, see supplementary methods) revealed their
convergence towards a set of highly effective cocktails (Fig 2; see also Supplementary Fig. 3
and Supplementary Table 3 and 4 (top) for data on the individual generations). In addition,
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Supplementary Spreadsheet 1 gives all of the data on both reagent combinations and
experimental measurements in tabular form.
Convergence of solutions derived from the IBEA’s search of the chemical library was
assessed by measuring the population average rank of the IBEA hypervolume (see
supplementary methods) and the three objective functions (IL-1β expression, number of
component reagents within combinations and LDH release (Fig. 3). The observed plateau in
IL-1β expression between generations 9 and 10 and very marginal decreases in LDH
decrease (Fig 3 top and bottom left respectively) were triggers to halt the IBEA-directed
search. By this stage, although not provably globally optimal, almost all IL-1β expression
had been ablated by some combinations, with negligible toxicity.
A particular strength of this algorithm is the ability to add and remove reagents to/from the
library during the evolution of the combinations 23 (see supplementary methods – reagent
removal / addition and data analysis), and generations 10 and 11 explored these a little
further. We also noted that many of the more successful reagent combinations contained the
p38 MAPK inhibitor SB203580.
Post-hoc analysis of the IBEA search of combinatorial chemical space
The search of combinatorial chemical space yielded 51 and 188 reagent combinations that
exhibited an inhibition of IL-1β expression that was greater than or equal to either 95 % or
70 % of the control response, respectively (Supplementary Table 3 and 4, (Top)) across all
generations. We chose to explore the inhibitory activities of other reagents independently of
SB203580 because these effects might have been ‘masked’ in the EA by the dominance of
SB203580 (70% (35/50)) of sampled combinations at generation 10 contained SB203580).
Thus, a ‘post hoc’ analysis was conducted of all data to assess the fitness contributions of
single reagents (their overall score against our defined objectives) alone and in two- and
three- component combinations (in the presence and absence of SB203580) for all reagents
(Fig. 4 and see Methods). These component reagents included the p38 MAPK inhibitor
(SB203580), a sphingosine kinase inhibitor, (SKI-II), a statin (simvastatin), an iron chelator
(SIH) and an inhibitor (BMS-345541) of the inhibitory κB kinase (IKKi). Inhibitors of p38
MAPK and IKK are well established as inhibitors of IL-1β expression, and (as well as its
effects on HMG-CoA reductase) simvastatin is a known anti-inflammatory and an
abundance of evidence implicates poorly liganded iron in inflammatory processes 24,25.
However, the appearance of SKI-II may have been unexpected, albeit that there is evidence
for the involvement of at least one sphingosine kinase in inflammation 26. Despite the
appearance of both wortmannin and the mitochondrial uncouplers in the post-hoc analysis,
these compounds were not pursued further owing to their lack of specificity and potential
toxicity, respectively. The ability to observe substantial inhibition of IL-1β expression with
just pairs of inhibitors (Supplementary Table 3 and 4 (bottom)) led us to study the
concentration-dependent pair-wise optimization of the top-ranked reagents.
Concentration-dependent search reveals combinatorial synergism
The search over defined concentration ranges of all pairs of five top-ranked reagents was
assessed using an adaptive dose matrix search protocol (Figure 1, Loop 2 and
Supplementary Fig. 4). Briefly, this protocol adaptively changes the concentrations of
chosen reagents (See methods and compare SB203580 and SIH (Supplementary Fig. 4)
versus the same combination presented here (Fig. 5)). Reagents were assessed alone and in
pairs (Fig 5). Modes of pharmacological effect driven by reagent combinations have their
own nomenclature 27-29. Hence, additivity is the linear superposition of two different reagent
effects and synergy a non-linear (excess) inhibition from a reagent combination beyond that
expected for simple additivity 27. Evidence of synergy (Fig 5(IKKi; c) or 5(SIH; f)) was
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determined by subtraction of predicted additive effects (Fig 5(IKKi; b) or 5(SIH; e)) of each
combination (based on single reagent efficacy) from the actual experimental data (Fig
5(IKKi; a) or 5(SIH; d)). Synergy was observed for most combinations; however, we noted
in some instances that this was in fact attributable to a loss of a potentiating effect on IL-1β
expression that occurred with either of the reagents when used alone. In these cases, the net
(i.e. resulting) magnitude of IL-1β inhibition was minimal and therefore we focus here on
examples of combinatorial synergy generating biologically-relevant levels of IL-1β
inhibition. SB203580 (0.1 μM) and IKKi (1 μM) alone inhibited IL-1β expression by 28 ± 7
% and 12 ± 9 % respectively (mean ± SEM, n=7) and SB203580 (0.1 μM) and IKKi (1 μM)
in combination achieved significantly greater inhibition than did either drug alone (59 ± 5
%, n=7, p< 0.02 and p< 0.0005, one way ANOVA with Tukey’s multiple test correction
versus SB203580 or IKKi alone respectively). The inhibitory effect of SB203580 (0.1 μM)
and IKKi (1 μM) in combination was 19% greater than that predicted for a purely additive
effect thus demonstrating a marked synergistic interaction at these concentrations (Fig. 5(c)).
Similarly, SB203580 (0.1 μM) and SIH (3 μM) alone inhibited IL-1β expression by 31 ± 10
% and 19 ± 8 % respectively (n=7 plates) and combinatorially inhibited IL-1β expression by
a significantly greater magnitude (59 ± 4 %, n=7 plates, p<0.04 and p< 0.004, one way
ANOVA with Tukey’s multiple test correction versus SB203580 and SIH alone,
respectively). This combinatorial inhibitory effect was 9% greater than that predicted for
pure additivity therefore indicating a synergistic interaction (Fig. 5(f)). We also observed
marked synergistic effects for combinations of IKKi and SKI-II, IKKi and SIH and
SB203580 and SIH (Supplementary Fig. 4), To assess whether a triple combination of
SB203580, IKKi and SIH could provide an inhibition of IL-1β expression beyond the
synergy already observed for both paired combinations (i.e SB203580 with either IKKi or
SIH) we superimposed increasing concentrations of SIH (0, 0.1, 0.3, 1 and 3 μM) onto
SB203580 and IKKi dose matrices (Supplementary Fig. 5). We did not observe any further
synergy with the triple-combination.
Discussion
There is a growing recognition that drugs, to be effective whether singly or in combination,
must affect multiple steps simultaneously 7,10,30,31. This, however, leads immediately to a
combinatorial explosion of experimental possibilities that limits the number of drugs that
can reasonably be tested exhaustively. We have applied a multi-objective evolutionary
algorithm (EA) to the optimization of reagent combinations, using a panel of candidate
reagents selected from our own studies and the literature 32 as targeting the pro-
inflammatory IL-1β expression network. The objective assessment of reagent combinations
arising from the IBEA-directed search utilizing the ‘post hoc’ analysis of reagent fitness
contributions is useful as it removes a layer of decision making 20, reducing bias and
potentially enhancing ‘hidden’ phenomena (e.g. off target effects of reagents) that may have
beneficial effects on the system output (i.e. IL-1β expression). In this regard, it is worth
mentioning the increasingly effective use of adaptive dosing regimes in clinical trials of
pharmaceutical drugs both singly and in combinations 33.
Combination therapy is now returning to the fore with a greater understanding of
pharmacological mechanism being uncovered by advances in parallel measurements of
biological endpoints 11,34,35 The use of the Gur-game stochastic search algorithm has been
reported 36,37 in elucidating the anti-viral and NF-κB-activating efficacy of drug and
cytokine combinations, respectively. Briefly, this algorithm functions by generating a
random number (e.g. one representing a specified anti-viral activity) and switching the
concentration of component drugs if their efficacy is below this value. In contrast, stochastic
and deterministic elements of our search were based on experimental data output and
recombination of reagents in new cocktails that had not yet been evaluated. In addition, the
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multi-objective nature of the EA-driven search presented here allows assessment of a
number of biological endpoints. Following this approach with an adaptive dose-matrix
driven search enabled a search of pharmacological space using just top-ranked ‘hits’.
Applications of search algorithms and the use of machine learning in the optimization of
combinatorial therapies have recently been reviewed 38, and within their categorization our
method would fall into “E – Model-free Biological Search”.
Recently, two papers have cited the pairing of reagent combinations as indicative /
predictive of higher order effects 39,40. The latter 40 used a series of chemotherapeutic
reagents to monitor for additivity, antagonism or synergy of combinations on YFP-tagged
protein dynamics in the H1299 cell line. The authors propose that a linear superposition of
weighted sums from the effect single drugs have on protein dynamics can predict higher
order (i.e. combinatorial) effects for these reagents, although they were unable to
demonstrate this for Wortmannin (a PI3K inhibitor). The former 39 looked for an
enhancement in the [Ca2+]i signal of platelets using a pairwise agonist scanning approach of
six reagents at three different concentrations. Using these data the authors trained a neural
network model to predict higher order effects and were successful in doing so. However, the
rapid and non-transcriptional signal transduction required for Ca2+ mobilization may not be
entirely reflective of multi-protein signalling networks, where there is extensive cross-talk
and feedback loops that modulate responses on timescales ranging in minutes to hours and
beyond. In the present case, we found a substantial inhibition of IL-1β production by the p38
MAPK inhibitor SB203580, that was enhanced synergistically by either the IKK inhibitor
BMS 345541 or the iron chelator SIH 41. Perhaps surprisingly, the triple combination of
SB203580, IKKi and SIH did not reveal additional effects beyond those observed for
pairwise combinations of SB203580 and either of the other two reagents. The effects of iron
chelation are of especial interest here, as there is abundant but widespread evidence for the
role of unliganded iron in a variety of inflammatory disorders 24,25,42.
p38 inhibitors have proved disappointing in clinical trials, but this is not so much because
they are not active in vivo but because (at the doses used) they lose specificity for the α
isoform of p38 and are toxic 43. The particular benefit of the synergy when combining a p38
inhibitor such as SB203580 with BMS345541 or SIH observed here is that we can use them
at lower concentrations in combinations than those at which they would be used alone (Fig
5). We note too that such inhibitors seem not to have been designed to exploit the specificity
of pharmaceutical drug transporters 44. Finally, it was noted too the efficacy of some
combinations that did not involve the p38 inhibitor.
In conclusion, the application of an EA in conjunction with semi-automated assay of a
dynamic chemical library enables a rapid scanning of reagent combinations without the need
of initial hypotheses 45 about likely higher-order effects. Our results show that synergistic
combinations can be revealed quickly, and that these combinations survived further
experimental scrutiny, leading to pairwise combinations that seem promising to use in
practice. Synergism of the SB203580 and either IKKi or SIH combination presented here, in
contrast to the comparatively marginal effect of the individual reagents at the same
concentrations, shows that pharmacological modification of biological targets and processes
may be effected at concentrations that are more likely to avoid toxicities. This has particular
relevance to the treatment of chronic inflammatory conditions such as irritable bowel
syndrome46 and chronic obstructive pulmonary disease 47 where treatment may be
maintained for extensive periods. Our approach is essentially generic, and the time required
per generation is determined by the time needed for setting up and running the assays
(typically 3 days, one each for cell preparation, combination preparation and ELISA
analyses), since the time needed for the algorithm to analyse the results and then to choose
the cocktails for the next generation was negligible in comparison. Overall, our new method
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substantially decreases the time taken for the triage of pharmacologically useful chemical
diversity within chemical libraries 48. Additionally, we demonstrate how combinations of
known drugs or reagents could allow them to be repurposed 49 and could provide an elegant
adjunct to existing therapeutic strategies in chronic inflammatory conditions.
Methods
All procedures, protocols and methods were carried out under aseptic conditions where
deemed necessary.
Construction and composition of the chemical library
The choice of reagents with which to populate the chemical library searched here was
guided in part by Oda and Kitano’s TLR signalling network 32 and via identification of
suitable ligands from single reagent studies in peritoneal macrophages. The following
pharmacological classes of reagents were used: Iron chelators, TPEN; a zinc chelator, anti /
pro-oxidants, NADPH oxidase inhibitors, PI3Kinase inhibitors, MAPK pathway inhibitors,
NF-κB pathway inhibitors, Genistein; a tyrosine kinase inhibitor, mitochondrial uncouplers
(removed after generation 3), statins and small-GTPase inhibitors. In the evolutionary
optimization process each of these reagents corresponds to a single binary variable
indicating whether the reagent is included in a combination or not; the combination itself
represents a candidate solution to the problem. Detailed information regarding the
construction, storage, maintenance and removal and replacement of reagents within the
chemical library can be found in the supplementary methods (Reagent removal / addition
and data analysis).
Implementation of the Indicator Based Evolutionary Algorithm (IBEA)
In order to select a suitable multi-objective evolutionary algorithm (EA) for addressing the
search of the fitness landscape of the chemical library, a comparison of four EAs; IBEA,
SPEA2 and NSGA2 with binary tournament and NSGA2 with probabilistic selection 50 was
undertaken 23. All EAs were assessed on a family of test problems used to simulate the
reagent combination problem. The test problems model a scenario where pharmacological
interactions among reagents can be described by single, binary, and ternary effects only. A
reagent combination can effect minimal IL-1β expression by killing cells; measured as a
large release of LDH. To de-risk the detection of lethal versus effective and benign
combinations respectively, positive, negative, and no correlations were considered between
these two objectives. The different levels of correlation were realized by assigning certain
probabilities to effect values; first for IL-1β expression and dependent on this value a
subsequent probability determining an effect value for the LDH release. Depending on the
correlation level, the effect values were drawn uniformly from the interval [−1,0) and/or
(0,1].
All EAs tested were capable of locating combinations of compounds of similar quality in the
presence of 80 % and 10 % variability in IL-1β expression and LDH release measurements
respectively. However, IBEA had the best performance at finding effective compound
combinations that contained only a few compounds (although its search was unrestricted and
could have used any number of compounds). This was the only EA tested that was not based
on Pareto ranking; rather IBEA searches for those solutions that maximize their
hypervolume within objective space. Initialization of the 1st generation of reagent
compounds in IBEA was conducted by fixing the probability of compound selection to 3 /
33 to ensure a random selection of compounds from across the library, with on average three
compounds in a cocktail. See the Supplementary methods (IBEA directed evolutionary
Small et al. Page 7
Nat Chem Biol. Author manuscript; available in PMC 2012 June 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
search of combinations inhibiting IL-1β expression) and results (Supplementary table 2) for
other details of the algorithm and its parameters.
Production and assay of reagent combinations
A Sciclone ALH3000 laboratory robot (Caliper Life Sciences) under the indirect control of
an Indicator Based Evolutionary Algorithm (IBEA) enabled the semi-automated assay of
chemical combinations (Supplementary methods – Production of combinatorial chemical
cocktails) in LPS stimulated J774.A1 macrophages. The iterative searching and analysis of
incremented generations of combinations was conducted via measurements of an IL-1β
expression ELISA (R&D Systems; DY401) and LDH release (Promega) (see Supplementary
methods – Measurement of LDH and IL-1β expression).
Treatment of Peritoneal and J774.A1 macrophages with single reagents and combinations
Peritoneal and J774.A1 macrophages were prepared and cultured (see supplementary
methods) for either single reagent or combinatorial and dose matrix studies respectively.
Peritoneal macrophages were exposed to either single reagents (0.01 μM - 100 μM) or
DMSO (0.5 % v/v) for 0.5 h prior to stimulation with LPS (1 μg / mL). Similarly, J774.A1
macrophages were treated with chemical combinations (3 μM or varying concentration) or
DMSO (0.5 % v/v or 0.1% v/v) during the EA-directed and adaptive dose-matrix search
respectively for 10 min prior to stimulation with LPS (1 μg / mL). After 4 h (Peritoneal) or 2
h (J774.A1) aliquots of well supernatants were taken for the measurement of LDH during
single-reagent and EA driven combinatorial assessment respectively (see supplementary
methods) prior to disposal of remaining supernatant, lysis of cells and freezing before
measurement of IL-1β expression (see Supplementary methods – Measurement of LDH and
IL-1β expression).
Post-hoc analysis of IBEA search and calculation of reagent fitness
Calculation of the fitness contribution of a single reagent within a combination was assigned
as follows (1):
(1)
Where; Fi is the fitness contribution of any given single reagent (i), and where  and  are
the mean IL-1β expression values of all combinations where this single reagent (i) was
present or absent respectively. Thus, a larger fitness contribution Fi indicates that a reagent
is more efficient in decreasing IL-1β expression.,
Concentration-dependent optimization of paired reagent combinations using an adaptive
dose matrix search protocol
Upon completion and post-hoc prioritization of reagent combinations from the IBEA search
a concentration-dependent optimization step was implemented. Briefly, to assess the
potentially synergistic effects of paired combinations on IL-1β expression we serially and
logarithmically decreased the test concentrations of reagents from those used during the EA-
directed search. Similarly, after this initial optimization step, we extended the scanned
concentration ranges of promising combinations by adding in test concentrations of reagents
at approximate 0.5 log10 spacings within the dose-matrix. This allowed effect (i.e. IL-1β
expression) comparisons at multiple doses of paired reagents. Pseudocolor mappings were
performed by linear interpolation between samples; those mappings that move away from
the blue end of the spectrum within combination response shape plots are indicative of
synergistic inhibition of IL-1β expression between two reagents. (Figure 5, Supplementary
Fig 4).
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Combinatorial evolutionary inhibition of IL-1β expression (Loop 1, clockwise, black
arrows). Known drugs were tested alone before being used at a single concentration (3μM)
in a chemical library. Initialization of the Indicator Based Evolutionary Algorithm (IBEA)
creates a random selection of combinations that are incubated with stimulated cells before
measurement of cell death (LDH release) and IL-1β expression. Evaluation of these data
against the number of compounds in the combination (All data n = 3) is performed by IBEA
prior to a new generation of combinations being computed and tested. After 11 generations,
concentration-dependent optimization (Loop 2) of five top-ranked reagents was undertaken.
Synergy was detected in novel dual-combinations.
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Figure 2.
Analysis of successive generations (Generations 1; initialization, 5 and 10) of reagent
combinations reveals their convergence to a subset of highly effective combinations
reflecting the inhibition of IL-1β expression with concomitant decreases in LDH release and
the number of member reagents. All data presented are the means of 3 determinations. Data
points appearing as zero on the number of (#) reagents axis were reflective of positive
control responses (LPS (1 μg / mL) and DMSO (0.5 % v/v).
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Figure 3.
Population average rank for inhibition of IL-1β expression (top left), number of component
reagents in combinations (top right), LDH release (bottom left) and overall IBEA
hypervolume (bottom right) respectively. Error bars are the standard errors. The IBEA
hypervolume is a composite (see Methods; Implementation of the Indicator Based
Evolutionary Algorithm (IBEA)) of the performance of the different generations with regard
to the three objectives, a smaller number being better.
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Figure 4.
Analysis of all EA generations (1 – 11) in the presence (top) and absence (bottom) of
SB203580 yielded a rank order for the fitness contribution (see Methods; Post-hoc analysis
of IBEA search and calculation of reagent fitness) of each reagent within the library. Only
five top ranked reagents are displayed here either alone (i.e. single) or in double or triple
combinations in the presence and absence of SB203580.
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Figure 5.
Concentration-dependent adaptive dose matrix optimization of paired reagent combinations
was achieved by adaptively changing the concentrations of reagents after assessing the
inhibition of IL-1β expression. A p38 MAPK inhibitor (SB203580) and an Iκ Kinase
inhibitor (IKKi) (a) or an iron chelator (SIH) (d) were assessed alone and as paired
combinations. Potential synergy of the SB203580 & IKKi (c) and SB203580 & SIH (f)
combinations were revealed by subtraction of simple additive effects ((b) and (e); calculated
from single reagent data in the absence of the other reagent respectively) of the respective
combinations from the experimental data (a) & (d). Synergistic inhibition of IL-1β
expression was revealed with the combinations of SB203580 & IKKi (c) and SB203580 &
SIH (f) as an ‘extra’ inhibition additional to the additive inhibitions of the individual
reagents taken together.
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